SUBOXONE

SUBOXONE is a sublingual tablet containing buprenorphine and naloxone, approved by the FDA in October 2002 for the treatment of opioid dependence. Buprenorphine functions as a partial agonist at mu-opioid receptors while antagonizing kappa-opioid receptors, providing a safer alternative to full opioid agonists. Naloxone, a mu-opioid antagonist, is included to deter misuse via parenteral routes. SUBOXONE represents a cornerstone therapy in medication-assisted treatment (MAT) for opioid use disorder and is widely considered the standard-of-care maintenance therapy in outpatient settings.